Citi analyst Yigal Nochomovitz lowered the firm’s price target on Crispr Therapeutics (CRSP) to $82 from $89 and keeps a Buy rating on the ...
Images from the scene show activists waving banners outside Inverness Airport declaring ‘Ban Private Jets’ and ‘Blackbird Nae ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback